Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Therapy of the Effects of Donepezil-iGaLa Combined Therapy in Post-Stroke Chronic Aphasia
2024-518763-35-00Phase 3Withdrawn
- Sponsor
- Fundación IMABIS
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of donepezil in post-stroke aphasia, sponsored by Fundación IMABIS. Planned start Feb 2025; status: withdrawn.
02
Drugs
donepezil
03
Conditions
post-stroke aphasia
Beyond the preview
Go deeper on 2024-518763-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518763-35-00.